The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
Lee S. Rosen(APLA Health), Niall C. Tebbutt(Austin Health), Herbert I. Hurwitz(Duke Medical Center), Cheng‐Pang Hsu(Amgen (United States)), Timothy Price(Basil Hetzel Institute), Sheryl McCoy(Amgen (United States)), Joe Stephenson(Neurology Centers of the Carolinas), Neil D. Belman(Lehigh Valley Hospital-Pocono), Ralph V. Boccia(Center for Cancer and Blood Disorders), Lara Lipton(The Royal Melbourne Hospital), Yong-Jiang Hei(Amgen (United States)), Lori J. Wirth(Massachusetts General Hospital)
Cited by 11
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k